Brief: United Laboratories International Says Unit Received Approval Of Clinical Trial By NMPA
April 14 (Reuters) - United Laboratories International
Holdings Ltd 3933.HK :
* UNIT RECEIVED NOTICE OF APPROVAL OF CLINICAL TRIAL BY NMPA
FOR
INSULIN DEGLUDEC AND LIRAGLUTIDE INJECTION
Further company coverage: 3933.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on United Laboratories International Holdings
See all newsBrief: United Laboratories International Receives Milestone Payment From Novo
Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
Brief: United Laboratories International Posts HY Profit Attributable RMB 347.6 Million
China's United Laboratories half-year profit drops 82%
Brief: United Laboratories International Expects HY Net Profit RMB 340 Million